This project was developed in close collaboration with Esteve Quimica and it was funded by a national grant from the CDTI. The main objective was to evaluate and develop innovative routes of synthesis for generic products or APIs closed to patent expiration. To do so, it is important to identify new routes with a clear competitive advantage in terms of cost or yield, and/or using cheaper intermediates or catalysts, and/or using cleaner and more efficient technologies.
Exploitation of results
- Patent Preparation process of an agonist of the thrombopoietin receptor (EP2799425A1, WO2014177517A1).
GalChimia thanks all the partners of the consortium for their involvement and teamwork, which have been key to the success of the project.